Cencora, Inc. (NYSE:COR) Shares Purchased by Assetmark Inc.

Assetmark Inc. boosted its holdings in Cencora, Inc. (NYSE:COR) by 33.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,536 shares of the company’s stock after buying an additional 641 shares during the quarter. Assetmark Inc.’s holdings in Cencora were worth $571,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. New Millennium Group LLC acquired a new position in Cencora in the 2nd quarter worth approximately $26,000. TFO Wealth Partners LLC acquired a new position in Cencora in the 1st quarter worth approximately $30,000. LRI Investments LLC acquired a new position in Cencora in the 1st quarter worth approximately $31,000. MFA Wealth Advisors LLC acquired a new position in Cencora in the 2nd quarter worth approximately $30,000. Finally, Concord Wealth Partners acquired a new position in Cencora in the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Bank of America reissued a “neutral” rating and set a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Wells Fargo & Company lifted their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Evercore ISI lifted their target price on shares of Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Barclays lifted their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Cencora Stock Down 1.1 %

Shares of NYSE:COR opened at $240.24 on Friday. Cencora, Inc. has a 52 week low of $194.23 and a 52 week high of $251.56. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The company has a market capitalization of $47.34 billion, a PE ratio of 31.99, a PEG ratio of 1.66 and a beta of 0.44. The company has a 50 day moving average price of $232.62 and a two-hundred day moving average price of $231.08.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.92%. Cencora’s dividend payout ratio is currently 29.29%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.80% of the stock is owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.